Triple therapy of chronic hepatitis C virus (HCV) infection with boceprevir (BOC) or telaprevir (TVR) leads to virologic failure in many patients which is often associated with the selection of resistance-associated variants (RAVs). These resistance profiles are of importance for the selection of potential rescue treatment options. In this study, we sequenced baseline NS3 RAVs population-based ...

background: nowadays, the immune response to hepatitis c (hcv) treatment has become a crucial issue mostly due to the interleukin 28b (il-28b) polymorphism effects in chronic hcv patients. the aim of this study was to detect the polymorphism of il-28b gene (rs12979860) in hcv genotype 1 patients treated with pegylated interferon and ribavirin. methods: from the 2010 to 2012, a total of 115 peri...

BACKGROUND Interferon-α in combination with ribavirin is the current gold standard for treatment of chronic hepatitis C. It is unknown if the development of autoimmune thyroid disease (TD) during treatment confers an improved chance of achieving sustained virologic response. The aim of this study is to assess the chance of achieving sustained virologic response (SVR) in patients who developed T...

Authors have reported conflicting results on the persistence of hepatitis C virus (HCV) infection in patients having sustained virologic response (SVR) to treatment. Therefore, we sought to determine whether chemotherapy leads to viral relapse in 30 HCV-infected patients who had SVR before cancer diagnosis. Half of them had hematologic malignancies. Most (60%) received HCV therapy with interfer...

Sustained virologic response (SVR) is defined as aviremia 24 weeks after completion of antiviral therapy for chronic hepatitis C virus (HCV) infection. In analyses of SVR durability, the incidence of late relapse is extremely low (<1%). Histologic regression of both necroinflammation and fibrosis has been demonstrated in paired liver biopsy samples in SVR-achieving patients. More noteworthy is ...

BACKGROUND Peginterferon (PEG-IFN) α-2a has been shown to induce a sustained virologic response (SVR) in 20-30% of "hepatitis B e antigen (HBeAg)"-negative patients. AIM To determine the safety and efficacy of PEG-IFN α-2a in HBeAg-negative, genotype D-naive patients and to analyze the predictors of response. METHODS This prospective, multicenter, open-label, nonrandomized trial was conduct...

Current American Association for the Study of Liver Diseases and AmericanGastroenterological Association guidelines recommend 48 weeks of treatment with peginterferon and ribavirin (1000-1200 mg/day) for patients infected with hepatitis C genotype 1.1,2 The goal of treatment is a sustained virologic response (SVR) defined as a negative hepatitis C virus (HCV) RNA 6 months after therapy is stopp...

Background Approximately 30% of HIV-infected patients are coinfected with hepatitis C (HCV). The current treatment standard of care for HCV, pegylated interferon and ribavirin (RBV), has demonstrated a sustained virologic response (SVR) in less than 50% of HCV/HIV coinfected patients, and only 17-35% in HCV genotype 1 patients. It has been previously shown that using a weight-based RBV dose res...

We examined whether hepatitis C virus (HCV) genotype 1b core- and NS5A-region mutations are associated with response to peginterferon α-2b plus ribavirin combination therapy. A total of 103 patients with high HCV genotype 1b viral loads (≥ 100 KIU/mL) were treated with the combination therapy. Pretreatment mutations in the core region and interferon sensitivity determining region (ISDR) in the ...